Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/13/21 | Current report filing |
|
5 | ||
| 04/30/21 | Current report filing |
|
4 | ||
| 04/20/21 | Definitive proxy statements |
|
23 | ||
| 03/19/21 | SEC-generated letter |
|
1 | ||
| 03/16/21 | Registration statement for specified transactions by certain issuers |
|
50 | ||
| 03/15/21 | Annual report pursuant to Section 13 and 15(d) |
|
 |
82 | |
| 03/11/21 | Current report filing |
|
15 | ||
| 02/12/21 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
7 | ||
| 02/08/21 | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
9 | ||
| 01/06/21 | Statement of changes in beneficial ownership of securities |
|
1 |